在最近的一次试验中,新的肺结核治疗结果和安全性比标准疗法好。 A new TB treatment shows better results and safety than standard therapy in a recent trial.

生物维瑞斯及其合作伙伴开发的新型结核病治疗的第二阶段临床试验取得了有希望的结果,该研究发表在"新英格兰医学杂志"上. A phase 2a clinical trial for a new tuberculosis treatment developed by BioVersys and its partners has yielded promising results, published in the New England Journal of Medicine. 该研究评价了肺肺结核患者的新药物疗法,显示与标准疗法相比,细菌结关和安全情况有所改善。 The study evaluated a novel drug regimen in patients with pulmonary tuberculosis, showing improved bacterial clearance and safety profiles compared to standard therapy. 成果支持治疗的进一步发展,有可能为防治抗药性和常见的结核病提供更短、更有效的选择。 Results support further development of the treatment, potentially offering a shorter, more effective option for combating drug-resistant and common forms of TB.